Research Analysts’ Weekly Ratings Updates for Celldex Therapeutics (CLDX)

Celldex Therapeutics (NASDAQ: CLDX) recently received a number of ratings updates from brokerages and research firms:

• 9/23/2026 – Celldex Therapeutics had its price target raised by Leerink Partners from $70.00 to $88.00. They now have an “outperform” rating on the stock.
• 9/23/2026 – Celldex Therapeutics had its price target raised by Morgan Stanley from $50.00 to $57.00. They now have an “overweight” rating on the stock.
• 9/22/2026 – Celldex Therapeutics was given a new $68.00 price target by Stifel Nicolaus.
• 9/22/2026 – Celldex Therapeutics had its price target raised by HC Wainwright from $42.00 to $64.00. They now have a “buy” rating on the stock.
• 9/22/2026 – Celldex Therapeutics had its price target raised by Cantor Fitzgerald from $61.00 to $72.00. They now have an “overweight” rating on the stock.
• 9/10/2026 – Celldex Therapeutics had its price target raised by Morgan Stanley from $46.00 to $50.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Celldex Therapeutics had its price target raised by Morgan Stanley from $40.00 to $46.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Celldex Therapeutics had its price target raised by Barclays PLC from $48.00 to $53.00. They now have an “overweight” rating on the stock.

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.